2016
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
Publication
Publication
PharmacoEconomics p. 1- 12
The National Institute for Health and Care
Excellence (NICE) invited Janssen, the company manufacturing
abiraterone acetate (AA; tradename Zytiga), to
submit evidence for the clinical and cost effectiveness of
AA in combination with prednisone/prednisolone (AAP)
compared with watchful waiting (i.e. best supportive care
[BSC]) for chemotherapy-naı¨ve patients with metastatic
castration-resistant prostate cancer (mCRPC). Kleijnen
Systematic Reviews Ltd (KSR), in collaboration with
Maastricht University Medical Center, was commissioned
as the Evidence Review Group (ERG). This paper presents
a summary of the company submission (CS), the ERG
report, subsequent addenda, and the development of the
NICE guidance for the use of this drug in England and
Wales by the Appraisal Committee (AC). The ERG produced
a critical review of the clinical and cost effectiveness
of AAP based on the CS. An important question in this
appraisal was, according to the ERG, whether AAP followed
by docetaxel is more effective than BSC followed by
docetaxel.
...
Additional Metadata | |
---|---|
doi.org/10.1007/s40273-016-0445-5, hdl.handle.net/1765/98686 | |
PharmacoEconomics | |
Organisation | Erasmus School of Health Policy & Management (ESHPM) |
Ramaekers, B., Riemsma, R., Tomini, F., Deshpande, S, Duffy, S, Armstrong, N., … Joore, M. (2016). Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. PharmacoEconomics, 1–12. doi:10.1007/s40273-016-0445-5 |